CD39 transforming cancer therapy by modulating tumor microenvironment

被引：5

作者：

Xu, Suling ^{[1
]}

Ma, Yuhan ^{[1
]}

Jiang, Xinyu ^{[1
]}

Wang, Qingqing ^{[2
]}

Ma, Wenxue ^{[3
,4
]}

机构：

[1] Ningbo Univ, Affiliated Hosp 1, Dept Dermatol, Sch Med, Ningbo 315020, Zhejiang, Peoples R China

[2] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China

[3] Univ Calif San Diego, Sanford Stem Cell Inst, Dept Med, La Jolla, CA 92093 USA

[4] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

来源：

CANCER LETTERS | 2024年 / 597卷

关键词：

CD39; Tumor Microenvironment (TME); Immunoregulation; Angiogenesis; Metabolic reprogramming; Therapeutic targets; EXPRESSION; PROGNOSIS; SURFACE;

D O I：

10.1016/j.canlet.2024.217072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.

引用

页数：11

共 110 条

[1] Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics [J].

Akinsipe, Tosin ;

Mohamedelhassan, Rania ;

Akinpelu, Ayuba ;

Pondugula, Satyanarayana R. ;

Mistriotis, Panagiotis ;

Avila, L. Adriana ;

Suryawanshi, Amol .

FRONTIERS IN IMMUNOLOGY, 2024, 15

[2] The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets [J].

Allard, Bertrand ;

Longhi, Maria Serena ;

Robson, Simon C. ;

Stagg, John .

IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :121-144

[3] On the mechanism of anti-CD39 immune checkpoint therapy [J].

Allard, David ;

Allard, Bertrand ;

Stagg, John .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)

[4] Pragmatism as a paradigm for patient-oriented research [J].

Allemang, Brooke ;

Sitter, Kathleen ;

Dimitropoulos, Gina .

HEALTH EXPECTATIONS, 2022, 25 (01) :38-47

[5] Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies [J].

Anderson, Kristin G. ;

Braun, David A. ;

Buque, Aitziber ;

Gitto, Sarah B. ;

Guerriero, Jennifer L. ;

Horton, Brendan ;

Keenan, Bridget P. ;

Kim, Teresa S. ;

Overacre-Delgoffe, Abigail ;

Ruella, Marco ;

Triplett, Todd A. ;

Veeranki, Omkara ;

Verma, Vivek ;

Zhang, Fan .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)

[6] Immunity, inflammation and cancer: a leading role for adenosine [J].

Antonioli, Luca ;

Blandizzi, Corrado ;

Pacher, Pal ;

Hasko, Gyoergy .

NATURE REVIEWS CANCER, 2013, 13 (12) :842-857

[7] Metabolic programming and immune suppression in the tumor microenvironment [J].

Arner, Emily N. ;

Rathmell, Jeffrey C. .

CANCER CELL, 2023, 41 (03) :421-433

[8] Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia [J].

Aroua, Nesrine ;

Boet, Emeline ;

Ghisi, Margherita ;

Nicolau-Travers, Marie-Laure ;

Saland, Estelle ;

Gwilliam, Ryan ;

de Toni, Fabienne ;

Hosseini, Mohsen ;

Mouchel, Pierre-Luc ;

Farge, Thomas ;

Bosc, Claudie ;

Stuani, Lucille ;

Sabatier, Marie ;

Mazed, Fetta ;

Larrue, Clement ;

Jarrou, Latifa ;

Gandarillas, Sarah ;

Bardotti, Massimiliano ;

Picard, Muriel ;

Syrykh, Charlotte ;

Laurent, Camille ;

Gotanegre, Mathilde ;

Bonnefoy, Nathalie ;

Bellvert, Floriant ;

Portais, Jean-Charles ;

Nicot, Nathalie ;

Azuaje, Francisco ;

Kaoma, Tony ;

Joffre, Carine ;

Tamburini, Jerome ;

Recher, Christian ;

Vergez, Francois ;

Sarry, Jean-Emmanuel .

CANCER DISCOVERY, 2020, 10 (10) :1544-1565

[9] Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy [J].

Augustin, Ryan C. ;

Leone, Robert D. ;

Naing, Aung ;

Fong, Lawrence ;

Bao, Riyue ;

Luke, Jason J. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)

[10] Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity [J].

Bastid, Jeremy ;

Regairaz, Anne ;

Bonnefoy, Nathalie ;

Dejou, Cecile ;

Giustiniani, Jerome ;

Laheurte, Caroline ;

Cochaud, Stephanie ;

Laprevotte, Emilie ;

Funck-Brentano, Elisa ;

Hemon, Patrice ;

Gros, Laurent ;

Bec, Nicole ;

Larroque, Christian ;

Alberici, Gilles ;

Bensussan, Armand ;

Eliaou, Jean-Francois .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) :254-265

← 1 2 3 4 5 6 7 8 9 10 →